In spite of the indicated usefulness of doxorubicin in ILP for the treatment of sarcoma, we and others observed dose-limiting local toxicity after a TNF-based ILP with conventional doxorubicin (Di Filippo et al, 1999; Van Der Veen et al, 2000). The gene discussed is TNF; the disease is sarcoma.